Atara Biotherapeutics (NASDAQ:ATRA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a sell rating to a hold rating in a report released on Sunday.

ATRA has been the subject of a number of other research reports. Canaccord Genuity Group set a $13.00 price objective on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings cut shares of Atara Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. Finally, Freedom Capital raised shares of Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $9.50.

Atara Biotherapeutics Price Performance

Shares of ATRA opened at $8.72 on Friday. The firm has a market cap of $78.57 million, a P/E ratio of -7.39 and a beta of 0.12. The stock has a 50 day simple moving average of $9.35 and a two-hundred day simple moving average of $7.35. Atara Biotherapeutics has a 1 year low of $3.92 and a 1 year high of $19.15.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported ($0.32) EPS for the quarter, meeting analysts’ consensus estimates of ($0.32). The business had revenue of $0.63 million for the quarter, compared to analysts’ expectations of $0.55 million. Atara Biotherapeutics had a negative net margin of 269.42% and a negative return on equity of 79.12%. On average, equities analysts anticipate that Atara Biotherapeutics will post -0.16 earnings per share for the current year.

Institutional Trading of Atara Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ATRA. Raymond James Financial Inc. purchased a new stake in shares of Atara Biotherapeutics during the second quarter valued at approximately $31,000. Dimensional Fund Advisors LP purchased a new position in shares of Atara Biotherapeutics in the fourth quarter worth $181,000. Walleye Capital LLC bought a new stake in Atara Biotherapeutics during the 4th quarter valued at $220,000. Quadrature Capital Ltd raised its holdings in Atara Biotherapeutics by 22.8% during the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 3,779 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Atara Biotherapeutics by 58.6% during the 4th quarter. Renaissance Technologies LLC now owns 30,040 shares of the biotechnology company’s stock valued at $543,000 after buying an additional 11,104 shares during the period. Institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.